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Infection with the severe acute respiratory syndrome cor-
onavirus-2 (SARS-CoV-2) was first identified in Decem-
ber 2019 and has since become a worldwide  pandemic, 
challenging and sometimes overwhelming healthcare 
systems as well as causing more than a million deaths 
thus far. In just 10 months, over 80,000 indexed publica-
tions have appeared that reference SARS-CoV-2 and the 
associated Coronavirus disease 2019 (COVID-19). In this 
article, we highlight 20 papers that are of particular rele-
vance to the critical care clinician. The papers are divided 
into four broad topics: manifestations of severe COVID-
19 disease, pharmacological therapy for COVID-19, ven-
tilatory support for COVID-19 acute respiratory distress 
syndrome (ARDS), and healthcare system and worker 
stress. This list is not designed to be comprehensive but 
rather to give the reader an overview of important early 
papers and their findings.
Manifestations of severe COVID‑19 disease
COVID-19-associated ARDS is the hallmark of severe 
COVID-19 infection. Although it fulfills clinical criteria 
for ARDS, there may be important differences between 
COVID-19 ARDS and “classical” ARDS. A prospec-
tive study by Graselli et al. of 301 patients with COVID-
19 ARDS highlighted several important differences. 
Firstly, mean static compliance was higher in COVID-19 
ARDS (42 vs 31 mL/cm  H2O) relative to classical ARDS, 
although most patients had static compliance within the 
95% confidence interval (CI) for classical ARDS [1]. Sec-
ondly, in COVID-19 ARDS static compliance and  PaO2/
FiO2 ratios did not correlate, indicating that hypoxemia is 
not closely tied to lung stiffness in these patients, unlike 
in classical ARDS. Finally, D-dimer levels were mark-
edly elevated in COVID-19 ARDS (median 1880  ng/
mL) and higher D-dimer levels correlated with increased 
dead space ventilation and higher mortality. In the sub-
set of patients who underwent CT angiogram, those with 
D-dimer levels above the median showed evidence of 
bilateral hypoperfusion. All of these data suggest a role 
for intravascular pathology in COVID-19 ARDS.
An autopsy study from Ackermann et  al. shed addi-
tional light on the differences between COVID-19 ARDS 
and classical ARDS [2]. The authors compared 7 lungs 
from patients with COVID-19 ARDS with 7 lungs from 
patients with influenza-associated ARDS. All of the lungs 
showed diffuse alveolar damage with perivascular T-cell 
infiltration; however, the COVID-19 lungs also showed 
widespread thrombosis with microangiopathy and angio-
genesis, confirming the presence of pulmonary vascular 
disease in patients with COVID-19 ARDS.
Early COVID-19 ARDS can present with relatively 
preserved aeration on chest imaging in spite of severe 
hypoxemia. In some patients this, early, high-compli-
ance phenotype evolves into a low-compliance pheno-
type with poor aeration. Gattinoni et al. described these 
2 clinical presentations as the “L-type” (Low elastance, 
high compliance, preserved aeration) and “H-type” (High 
elastance, low compliance, poor aeration) phenotypes. 
Although they likely describe a continuous and dynamic 
spectrum of disease, the concept of inhomogeneous phe-
notypes of COVID-19-ARDS illustrates important clini-
cal descriptions and may have therapeutic implications.
Thrombosis is another frequent complication of 
COVID-19. Bilaloglu et al. reported on thrombotic com-
plications in a retrospective cohort of COVID-19 patients 
from New York [3]. Out of 3334 hospitalized patients, 
16% suffered at least one thrombotic event (6.2% venous 
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vs 11.1% arterial), whilst amongst 829 ICU patients, the 
rate was 29.4% (13.6% venous vs 18.6% arterial). Age, sex, 
Hispanic ethnicity, coronary artery disease, prior MI, and 
higher D-dimer levels at hospital presentation were all 
associated with risk for thrombotic events. The occur-
rence of a thrombotic event was independently associ-
ated with increased mortality.
Panigada et  al. quantified the hypercoagulability of 
COVID-19 in 24 critically-ill patients using plasma 
markers and thromboelastography [4]. Although plate-
let counts, prothrombin time, and activated partial 
thromboplastin time were near-normal, fibrinogen and 
D-dimer levels were dramatically increased. Thromboe-
lastography revealed a state of hypercoagulability, as indi-
cated by decreased clotting times and increased velocity 
of clot formation. Studies of anticoagulation for the pre-
vention and treatment of COVID-19 and its complica-
tions are underway.
Other extra-pulmonary manifestations of COVID-19 
infection have been reported including neurologic com-
plications (stroke, encephalopathy, anosmia), cardiac 
complications (acute coronary syndrome, myocarditis, 
arrhythmia, Takotsubo cardiomyopathy), renal com-
plications (acute kidney injury), hepatic complications 
(transaminitis), and gastrointestinal complications (diar-
rhea, nausea and vomiting, anorexia). Gupta et al. sum-
marized the data on these diverse complications and 
explored the relationship between the virus, its direct 
cytotoxic effects, its effects on the renin–angiotensin–
aldosterone systems, its effects on the endothelium, and 
the diverse manifestations of COVID-19 disease [5].
The concept of “cytokine storm” in severe COVID-19 
disease has also received widespread attention. Although 
it is imprecise, the term “cytokine storm” implies a hyper-
active immune response leading to  host tissue damage. 
Early studies reported that patients with COVID-19 
ARDS had higher levels of interleukin-6 (IL-6), a key 
inflammatory cytokine, relative to those with milder 
COVID-19 disease. However, in the broader context of 
ARDS, it appears that IL-6 levels in COVID-19 patients 
are not particularly high. Sinha et al. compared the data 
on IL-6 levels in COVID-19 ARDS relative to “classical” 
ARDS [6]. On average, IL-6 levels were 10–40x higher 
in “classical ARDS”, casting doubt on whether IL-6 lev-
els are a major contributor to COVID-19 severity. This 
may explain why IL-6-targeted therapies have yet to show 
convincing benefit (see below), although further studies 
are ongoing.
Pharmacological therapy for COVID‑19
International efforts have translated into extraordi-
nary progress in identifying and testing potential thera-
pies for COVID-19  (Fig.  1). One of the most important 
studies to date  was the Randomized Evaluation of 
COVID-19 Therapy (RECOVERY) Trial, which com-
pared dexamethasone to standard of care in hospitalized 
COVID-19 patients. Dexamethasone reduced mortality 
from 25.7% to 22.9% overall, and from 41.4% to 29.3% 
amongst patients  requiring invasive mechanical ventila-
tion (IMV) [7]. A follow-up meta-analysis confirmed the 
beneficial effects of corticosteroids in critically ill patients 
using  data pooled from 7 randomized control trials 
(RCTs) of corticosteroids vs placebo or standard of care 
[8]. The authors reported a summary odds ratio of 0.66 
(95% confidence interval (CI) 0.48–1.01; p < 0.001) for 
mortality in ICU patients with the use of corticosteroids.
Other immunomodulatory therapies have so far failed 
to show convincing  benefit. Tocilizumab, a monoclo-
nal antibody that blocks the interleukin-6 receptor, 
appeared beneficial in early observational studies. How-
ever, a recent RCT from Stone et  al. did not show ben-
efit amongst 243 patients with COVID-19 and lower 
respiratory tract involvement [9]. The hazard ratio for 
intubation or death in the treatment group was 0.83 (CI 
0.38–1.81) and there was an increase in the percentage of 
patients with worsening of disease at 14 days. Additional 
data on tocilizumab is expected shortly.
Remdesivir is a viral RNA synthesis inhibitor that has 
received attention as a potential antiviral therapy for 
COVID-19. The Adaptive COVID-19 Treatment Trial 
(ACTT-1) trial studied remdesivir vs placebo in hospi-
talized patients with COVID-19 and lower respiratory 
tract involvement [10]. Patients who received remdesivir 
(n = 541) had a median recovery time of 11  days, com-
pared to 15 days for placebo (n = 521). The hazard ratio 
for mortality at day 29 was 0.73 (95% CI 0.52–1.03), how-
ever no benefit was observed amongst patients receiving 
invasive or non-invasive ventilation.
Remdesivir, along with three other repurposed antivi-
ral drugs, was also studied in the WHO-SOLIDARITY 
Trial, a multinational platform trial that randomized 
11,266 adults from one to four drugs: hydroxychloro-
quine, lopinavir/ritonavir, remdesivir, or interferon-β1a 
[11]. Outcomes were hospital mortality, initiation of ven-
tilation, and duration of hospitalization. None of the four 
drugs showed benefit amongst patients requiring IMV. 
Amongst patients not requiring IMV, the most promising 
was remdesivir, with a hazard ratio for mortality of 0.86 
(95% CI 0.67–1.39). Studies of remdesivir are ongoing to 
determine whether specific patient subgroups may ben-
efit in terms of mortality.
Finally, convalescent plasma showed promise in early 
observational studies of COVID-19, but RCT data have 
been less convincing. Simonovich et  al. reported the 
results of the largest RCT to date, involving 333 patients 
with COVID-19 pneumonia who were randomized to 
convalescent plasma vs placebo in a 2:1 ratio [12]. No 
mortality difference was observed between the two 
groups (11% vs 11.4%) and there were no significant 
differences in clinical outcomes. Additional RCTs of 
convalescent plasma are underway, as are studies of mon-
oclonal and polyclonal antibody preparations.
Ventilatory support in patients with ARDS 
secondary to COVID‑19
One of the mainstays of ARDS management is invasive 
mechanical ventilation (IMV). Ferrando et  al. published 
a multicentre observational cohort study of 742 patients 
with COVID-19-ARDS on IMV during the first wave of 
the pandemic [13]. In this cohort, the average  PaO2/FiO2 
ratio at the time of intubation was 120 with a compliance 
of 35 ml/cmH2O, plateau pressure of 25  cmH2O, and pos-
itive end-expiratory pressure (PEEP) of 12  cmH2O. Dura-
tion of ventilation was prolonged, with an average of only 
4 ventilator-free days at day 30. Mortality at 28 days was 
32% but was lower for patients with mild ARDS (24%) 
relative to those with moderate or severe ARDS (29% and 
39%, respectively).
Many centres are using high flow nasal oxygen (HFNO) 
to try and reduce the need for IMV. Although there are no 
RCT data available, Zucman et al. published a retrospec-
tive single-centre study of 62 COVID-19 patients treated 
with HFNO during the first wave of the pandemic: 34% 
succeeded on HFNO, 63% required intubation, and 3% 
died on HFNO after a decision not to intubate [14]. A 
ROX index [(SpO2/FiO2)/Respiratory Rate] ≥ 5.37 within 
4 h of initiation of HFNO predicted a lower risk of intu-
bation and showed reasonable discrimination (sensitivity 
0.66, specificity 0.83). It is still unclear, however, whether 
HFNO actually reduces the need for IMV.
Prone positioning is also widely used to treat hypox-
emia in COVID-19 ARDS, including in awake patients. 
Fig. 1 COVID-19-ARDS: potential mechanisms and therapeutic options. Infection with the SARS-CoV-2 virus has direct cytotoxic effects on the 
lung as well as indirect effects via thrombosis and inflammation. Only one therapy has shown mortality benefit (red) in randomized control stud-
ies of COVID-19-ARDS, which is corticosteroids. Two additional therapies have shown reduced time to resolution of symptoms (green): remde-
sivir and baricitinib (data not included in article). Therapeutic options that are under investigation (grey) include convalescent plasma, synthetic  
antibodies with antiviral activity, tocilizumab, and anticoagulation. Ventilatory options for COVID-19 ARDS are also under investigation, including 
high flow nasal oxygen (HFNO), extracorporeal membrane oxygenation (ECMO), and proning, but have not yet been proven to be beneficial in 
randomized studies. Figure created using BioRender.com and Powerpoint 
Its utility in reducing the need for IMV and improving 
mortality are uncertain. Ferrando et al. published a pro-
spective multicentre observational study of 199 COVID-
19 patients receiving HFNO, of whom 55 participated in 
awake proning [15]. Patients treated with proning showed 
a trend towards later intubation (median = 1 day), but no 
reduction in IMV or 28 day mortality. Once again, rand-
omized data are not yet available.
For COVID-19 patients on IMV with severe hypox-
emia, extracorporeal membrane oxygenation (ECMO) is 
sometimes used as a rescue strategy. Schmidt et al. pub-
lished a retrospective review of 83 patients with COVID-
19 who received ECMO between March and May 2020 
[16]. At 60  days post-ECMO initiation, 6% of patients 
were still on ECMO, 45% had been discharged from the 
ICU, 31% had died, and 18% were in the ICU but off 
ECMO. The authors noted that these outcomes were 
similar to previous cohorts of non-COVID-19-ARDS 
patients treated with ECMO.
Finally, Menk et al. described the evolving standard of 
care for COVID-19 ARDS [17]. The authors advocated 
lung protective ventilation with tidal volumes ≤ 6  mL/
kg of predicted body weight, limitation of driving pres-
sure to ≤ 15  cmH2O, individualized PEEP titration, con-
servative fluid management, and veno-venous ECMO 
for severe, untreatable hypoxemia. Most of these rec-
ommendations are extrapolated from studies of patients 
with “classical” ARDS. Until COVID-19-specific data are 
available, however, it is reasonable to adopt these recom-
mendations as best practice.
Healthcare organization and healthcare worker 
stress
The impact of the COVID-19 pandemic on hospital sys-
tems, healthcare workers, patients, and their families 
has been profound. Healthcare systems have struggled 
to provide care to large numbers of severely ill patients. 
Rimmelé et  al. published a multicentre retrospective 
observational study of 9809 patients with COVID-19 in 
French ICUs between January and April, 2020 [18]. They 
reported increased mortality in the regions of France 
with the highest rates of COVID-19 (Paris and the north-
east), as well as during periods with potentially fewer 
healthcare workers. These data highlight the dangers of 
overwhelming healthcare systems.
Managing patient surges has been a major challenge 
for hospitals and ICUs worldwide. Aziz et  al. published 
guidelines to help anticipate ICU needs in the event of a 
surge, including estimates of equipment and supplies per 
ICU patient admitted [19]. They also provided recom-
mendations on managing shortages of mechanical ven-
tilators, shortages of ICU staff, protecting staff against 
COVID-19, patient triage, and supporting families and 
staff.
Finally, the pandemic has taken a heavy toll on health-
care workers. Azoulay et  al. published a cross-sectional 
cohort study of 1058 French ICU healthcare workers 
during the first wave of the pandemic [20]. Symptoms of 
mental health disorders were common, including anxiety 
(50.4%), depression (30.4%), and peritraumatic dissocia-
tion (32%). Nurses reported more symptoms than physi-
cians, and females reported more symptoms than males. 
Other determinants of mental health issues included fear 
of being infected, inability to rest, inability to care for 
family, struggling with difficult emotions, regrets about 
restrictions in visitation policies, and witnessing hasty 
end-of-life decisions. Healthcare worker distress may 
lead to higher rates of burnout and should be a focus 
of healthcare systems as we look to the 2nd wave and 
beyond.
In the first year of the COVID-19 pandemic, the inter-
national critical care community has mobilized rapidly to 
develop a dynamic and ever-increasing body of knowl-
edge. Enormous advances have been made in charac-
terizing COVID-19 disease and identifying therapeutic 
options. Urgent research priorities in critical care include 
greater pathophysiological understanding of COVID-19; 
ongoing evaluation of direct antiviral, anti-inflammatory, 
and immune-focused treatments; optimal thromboem-
bolism prevention; optimal management of invasive and 
non-invasive  ventilation; determining  the influence of 
oxygenation and ventilation strategies on viral disper-
sion in healthcare environments; long-term outcomes 
of patients with COVID-19; and long-term effects of the 
pandemic on hospital systems and healthcare workers.
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